Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

SZSE:002118 Stock Report

Market Cap: CN¥473.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Jilin Zixin Pharmaceutical IndustrialLtd Past Earnings Performance

Past criteria checks 0/6

Jilin Zixin Pharmaceutical IndustrialLtd's earnings have been declining at an average annual rate of -66.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 50.2% per year.

Key information

-66.3%

Earnings growth rate

-66.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-50.2%
Return on equity-87.3%
Net Margin-793.4%
Next Earnings Update23 Aug 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jilin Zixin Pharmaceutical IndustrialLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:002118 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 23150-1,1896554
31 Dec 22144-1,1896507
30 Sep 22145-1,2196308
30 Jun 22153-1,17859513
31 Mar 22192-1,10559212
01 Jan 22247-99855610
30 Sep 21248-77026717
30 Jun 21294-69828612
31 Mar 21289-69626417
31 Dec 20286-70628316
30 Sep 20343-28031015
30 Jun 20463-20127316
31 Mar 20756-2033637
31 Dec 198597031840
30 Sep 19760-8229666
30 Jun 19997-4537276
31 Mar 191,1411935646
31 Dec 181,32517435646
30 Sep 181,85454243346
30 Jun 181,71553841541
31 Mar 181,49347238845
31 Dec 171,32737238141
30 Sep 171,0062473027
30 Jun 179252532790
31 Mar 178591882870
31 Dec 168201632830
30 Sep 168741423010
30 Jun 16755572950
31 Mar 16666452740
31 Dec 15633402710
30 Sep 15689682460
30 Jun 15690732500
31 Mar 15663472640
31 Dec 14776472710
30 Sep 14568-302720
30 Jun 1457972440
31 Mar 14626372220
31 Dec 13475501960
30 Sep 13411521640
30 Jun 13372511530
31 Mar 13430971350
31 Dec 12419861320
30 Sep 127161262220

Quality Earnings: 002118 is currently unprofitable.

Growing Profit Margin: 002118 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002118 is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.

Accelerating Growth: Unable to compare 002118's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002118 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.6%).

Return on Equity

High ROE: 002118 has a negative Return on Equity (-87.33%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/05 18:43
End of Day Share Price 2023/06/15 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jilin Zixin Pharmaceutical Industrial Co.,Ltd. is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
YANG QIAOChangjiang Securities Co. LTD.
Qiu Han HuangSealand Securities